



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 12.02.2025

Dear Sir/Madam,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Unit: Vista Pharmaceuticals Limited (BE Scrip Code:524711)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s. Vista Pharmaceuticals Limited held on Wednesday, the 12th day of February, 2025 at 03.00 P.M. at the registered office of the Company the following agenda items were duly considered and approved by the Board:

1. Un Audited financial results for the quarter ended 31.12.2024.
2. Limited Review Report for quarter ended 31.12.2024

The meeting of the Board of Directors commenced at 3.00 P.M.(IST) and concluded at 6.45 P.M. (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Vista Pharmaceuticals Limited



Dhananjaya Alli
Executive Director
(DIN: 00610909)



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,

Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585

E-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

VISTA PHARMACEUTICALS LIMITED								
CIN:L24239TG1991PLC012264								
Statement of Unaudited Financial Results for the Quarter and Year ended 31st December,2024								
(in Rs Lakhs)								
S.No	Particulars	Quarter ended				Year to date figures		Year ended
		December 31,2024	December 31,2023	September 30,2024	June 30,2024	December 31,2024	December 31,2023	March 31,2024
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income							
	a. Revenue from operations	255.50	170.45	249.46	179.50	684.46	715.53	1028.78
	b. Other income	12.19	2.41	0.70	7.11	20.00	23.58	33.34
2	Total Income (a+b)	267.69	172.86	250.17	186.61	704.46	739.11	1062.12
3	Expenses							
	a) Cost of Material Consumed	204.76	221.24	155.35	160.27	520.38	738.90	888.25
	b) Change in Inventories	44.78	-	-	-	44.78	0.00	0.77
	c) Employee benefits expense	51.54	45.49	47.87	44.97	144.37	131.74	179.47
	d) Finance costs	22.26	29.70	25.26	28.25	75.77	94.18	121.98
	e) Depreciation and amortization expense	18.69	18.34	18.34	18.32	55.35	53.92	71.97
	f) Other expenses	106.10	76.97	128.56	51.93	286.59	202.61	291.75
	g) Prior Period Expenses	-	1.24	-	-	0.00	25.65	25.67
	Total Expenses	448.13	392.98	375.37	303.74	1,127.24	1,247.01	1,579.86
4	Profit before tax (2-3)	(180.44)	(220.12)	(125.20)	(117.13)	(422.77)	-507.90	-517.74
5	Tax expense							
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	(48.21)	(57.23)	(27.83)	(31.43)	(107.47)	(47.63)	(66.54)
	(3) Previous year Income tax adjustment	-	-	-	-	-	-	-
6	Net Profit for the Period (4-5)	(132.23)	(162.89)	(97.37)	(85.71)	(315.30)	(460.27)	(451.20)
7	Other comprehensive income (OCI)							
	(a) (i) items that will not be reclassified to profit or loss	3.35	0.00	0.00	0.00	3.35	0.57	0.29
	(ii) tax on items that will not be reclassified to profit or loss	(0.72)	0.14	0.31	0.41	-	-	-
	(b) (i) items that will be reclassified to profit or loss	0.00	-	-	-	-	-	-
	(ii) income tax relating to items that will be reclassified to profit or loss	0.00	-	-	-	-	-	-
	Total Other Comprehensive income	2.63	0.14	0.31	0.41	3.35	0.57	0.29
8	Total Comprehensive income (6+7)	(129.60)	(162.75)	(97.06)	(85.29)	(311.95)	(459.70)	(450.91)
	Earnings per equity share							
	(Face value of Rs.2/- each)							
	(1) Basic	(0.07)	(0.33)	(0.31)	(0.15)	(0.53)	(1.05)	(1.03)
	(2) Diluted	(0.07)	(0.26)	(0.31)	(0.15)	(0.53)	(0.75)	(0.74)
	Paid-up equity share capital (face value of Rs.2/- each)	1,231.04	937.96	1,231.04	1,231.04	1,231.04	937.96	943.30

Notes:

1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.

2.The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 12th February, 2025

3.The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

4. Total Revenue for the current quarter reported Rs 267.69 Lakhs compared to Rs. 172.86 for the corresponding quarter of the previous year.

5. The Loss before tax for the current quarter is Rs.251.74 Lakhs compared to Loss Before tax of Rs.220.12 Lakhs for the corresponding quarter of the previous year.

6.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products. Hence, segmental reporting as per IND AS-108 is not made.

7.The results for the quarter ended 31st December 2024 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.

8.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.

9. The company is pleased to announce that it has been awarded the WHO Certificate, effective as of the date of this results release.


Place:Hyderabad
Date:12.02.2025

for Vista Pharmaceuticals Limited
Dr. Dhananjaya Alli
Whole Time Director
(DIN00610909)

Independent Auditor's Review Report on unaudited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Vista Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited ("the Company") for the quarter ended December 31, 2024 and year to date results for the period October 1st, 2024 to December 31, 2024 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to



obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.

Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY
Chartered Accountants
Firms Registration No: 009068S



D.Rama Krishna Reddy
Partner

Membership No. 209211
UDIN: 25209211BMJBNS3105

Place: Hyderabad

Date: February 12, 2025

